Novacyt shares fall on French refusal to refund virus test

PARIS (Reuters) - Shares in healthcare and clinical diagnostics company Novacyt fell on Tuesday after a French regulator decided not to approve its novel coronavirus test for reimbursement, dampening Novacyt's stellar stock market rally.France, in common with other European countries, is betting on mass testing for the covonavirus that causes the respiratory illness COVID-19, as part of its strategy to emerge safely from the epidemic.City laboratories in France that carry out testing almost..